As per the agreement, the use of pSivida’s technology as a delivery system for a treatment for dry age related macular degeneration (Dry AMD) will be evaluated.
pSivida president and CEO Paul Ashton said this is the second tech evaluation agreement for bioerodible Durasert technology since the company regained the rights to its intellectual property from Pfizer.
Neuron CEO Todd Brady said the combination of Durasert and its proprietary compounds may provide an exciting new approach to treating the devastating disease.